 Connection
Joshua Barocas to Analgesics, Opioid
This is a "connection" page, showing publications Joshua Barocas has written about Analgesics, Opioid.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.500 |
|
|
|
-
Jawa R, Tin Y, Nall S, Calcaterra SL, Savinkina A, Marks LR, Kimmel SD, Linas BP, Barocas JA. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Netw Open. 2023 04 03; 6(4):e237888.
Score: 0.532
-
Barocas JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, Beckwith CG, Linas BP, Walley AY. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 2019 07 01; 200:59-63.
Score: 0.406
-
Savinkina A, Jurecka C, Gonsalves G, Barocas JA. Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study. Int J Drug Policy. 2023 Nov; 121:104175.
Score: 0.137
-
Jurecka CA, Barocas JA. Using Evidence to Inform Legislation Aimed at Curbing Fentanyl Deaths. JAMA Health Forum. 2023 01 06; 4(1):e225202.
Score: 0.131
-
Doogan NJ, Mack A, Wang J, Crane D, Jackson R, Applegate M, Villani J, Chandler R, Barocas JA. Opioid Use Disorder Among Ohio's Medicaid Population: Prevalence Estimates From 19 Counties Using a Multiplier Method. Am J Epidemiol. 2022 11 19; 191(12):2098-2108.
Score: 0.130
-
Adams JW, Savinkina A, Hudspeth JC, Gai MJ, Jawa R, Marks LR, Linas BP, Hill A, Flood J, Kimmel S, Barocas JA. Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use-Associated Infective Endocarditis. JAMA Netw Open. 2022 Feb 01; 5(2):e220541.
Score: 0.123
-
Flam-Ross JM, Lown J, Patil P, White LF, Wang J, Perry A, Bailer D, McKenzie M, Thigpen A, Newman R, Lincoln M, Mckinney T, Bernson D, Barocas JA. Factors associated with opioid-involved overdose among previously incarcerated people in the U.S.: A community engaged narrative review. Int J Drug Policy. 2022 02; 100:103534.
Score: 0.121
-
Barocas JA, Eftekhari Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, Englander H, Linas BP. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clin Infect Dis. 2021 12 06; 73(11):e3661-e3669.
Score: 0.121
-
Jawa R, Stein MD, Anderson B, Liebschutz JM, Stewart C, Phillips KT, Barocas JA. Behavioral Risk Factors for HIV Infection in Hospitalized Persons Who Co-use Stimulants and Opioids. AIDS Behav. 2022 Apr; 26(4):1047-1055.
Score: 0.119
-
Hadland SE, Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Morgan JR, Barocas JA. Opioid use disorder and overdose among youth following an initial opioid prescription. Addiction. 2021 10; 116(10):2790-2800.
Score: 0.116
-
Barocas JA, Gai MJ, Amuchi B, Jawa R, Linas BP. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020 10 01; 215:108207.
Score: 0.111
-
Barocas JA. Commentary on Irvine et al. (2019): Barriers to implementing a successful roadmap for preventing opioid-related overdose deaths. Addiction. 2019 09; 114(9):1614-1615.
Score: 0.103
-
Barocas JA. Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics. Ann Intern Med. 2019 04 02; 170(7):509.
Score: 0.101
-
Barocas JA, Saitz R. Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs. Ann Intern Med. 2019 01 15; 170(2):127-128.
Score: 0.099
-
Thompson K, Barocas JA, Delcher C, Bae J, Hammerslag L, Wang J, Chandler R, Villani J, Walsh S, Talbert J. The prevalence of opioid use disorder in Kentucky's counties: A two-year multi-sample capture-recapture analysis. Drug Alcohol Depend. 2023 01 01; 242:109710.
Score: 0.032
-
Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 09; 117(9):2450-2461.
Score: 0.031
-
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 10; 117(10):2635-2648.
Score: 0.031
-
Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 08 01; 225:108764.
Score: 0.029
-
Morgan JR, Wang J, Barocas JA, Jaeger JL, Durham NN, Babakhanlou-Chase H, Bharel M, Walley AY, Linas BP. Opioid overdose and inpatient care for substance use disorder care in Massachusetts. J Subst Abuse Treat. 2020 05; 112:42-48.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|